2.3.
4.The Authors Reply: With regard to the comments by Schildgen et al., prolonged acute hepatitis A virus and HEV infections have been reported previously in both immunocompromised and nonimmunocompromised patients. 1,2 Our report indicated that HEV infection may evolve to chronic hepatitis in organ-transplant recipients. In addition, a unique case of HEV-related cirrhosis has recently been reported. 3 Schildgen et al. suggest that the evolution of HEV infection to chronic hepatitis is related to marked immunosuppression. They base their assumption on two studies of viral infections that appear to be unrelated to those that have been observed in organ-transplant recipients. We agree that the evolution of HEV infection to chronic hepatitis in the setting of marked immunosuppression may be a mechanism, since we have found a lower CD4+ cell count in patients in whom chronic hepatitis evolved than in patients who were clear of the virus. Hence, in HEV-infected transplant recipients, we suggest reducing immunosuppressive therapies that target T cells (i.e., mainly calcineurin inhibitors) in order to allow clearance of the virus.